PACTR202003484099670已完成未知
Serum Level of 8-Isoprostane in Patients with Oral Erosive Lichen Planus Before and After Treatment with Lycopene: A Randomized Controlled Clinical Trial
Oral Medicine Periodontology Diagnosis and Radiology Department Faculty of Dentistry Alexandria University0 个研究点目标入组 20 人开始时间: 2020年3月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Patients who are unresponsive to the conventional topical corticosteroid therapy and in need of systemic oral corticosteroids.
排除标准
- •Smoking and tobacco use in any form.
- •Pregnant and lactating females.
- •suspected restoration or drug-related reaction (Lichenoid Contact/Drug reaction).
- •any systemic disease ( Diabetes, liver disease, renal disease, any other autoimmune or collagen disease).
- •cutaneous Lichen Planus (Skin lesions associated with oral lesions).
- •Lesions showing any dysplastic changes in the biopsy specimen.
- •Patients receiving any kind of systemic or local treatment for LP for the past one month.
研究者
相似试验
尚未招募
不适用
8-Isoprostane biomarker levels in patients with high blood pressure and pulp necrosis with symptomatic apical periodontitisCTRI/2024/05/066734Chahat Singhal
尚未招募
不适用
Isofurans Production under Hyperbaric conditions: an observational study in patients with osteonecrosis secondary to radiotherapyOxidative stressExamination of IsofuransOsteonecrosisHyperbaric therapyInflammatory and Immune System - Normal development and function of the immune systemMusculoskeletal - Other muscular and skeletal disordersACTRN12612000336886Dr. Tomas Corcoran40
进行中（未招募）
1 期
Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.MedDRA version: 19.0Level: LLTClassification code 10028577Term: Myeloproliferative disorder NOSSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028576Term: Myeloproliferative disorderSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015495Term: Essential thrombocytosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015494Term: Essential thrombocythemiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10013238Term: Disorder myeloproliferativeSystem Organ Class: 100000004864EUCTR2016-001406-42-DKHæmatologisk Afdeling, Sjælland Sygehus, Roskilde100
进行中（未招募）
1 期
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.EUCTR2018-004179-11-NLRadboudumc38
尚未招募
不适用
Onderzoek naar de effectiviteit van octreotide in hereditary hemorrhagic telangiectasia patiënten metdaarbij gastrointestinale bloedingen.NL-OMON25382Radboudumc38